

The Synthesis of Bicyclic N^4 -Amino-2'-deoxycytidine Derivatives

by David Loakes, Rita Bazzanini¹⁾, and Daniel M. Brown*

Medical Research Council, Laboratory of Molecular Biology, Hills Road, Cambridge, CB22QH, UK

(Tel: (+ 44) 1223 248011; Fax: (+ 44) 1223 412178; e-mail: dmb@mrc-lmb.cam.ac.uk)


Dedicated to Prof. Dr. Frank Seela on the occasion of his 60th birthday

Nucleosides which have ambivalent tautomeric properties have value in a variety of nucleic acid hybridization applications, and as mutagenic agents. We describe here synthetic studies directed to stable derivatives of this kind of nucleoside based on N^4 -aminocytosine. Treatment of the 4-(1*H*-1,2,4-triazol-1-yl)-5-(chloroethyl)pyrimidinone nucleoside derivative **5** with hydrazine leads to formation of the 6,6-bicyclic pyrimido-pyridazin-7-one **3**, and with methylhydrazine to the corresponding fixed tautomeric 1-methyl derivative **7** (*Scheme 1*). If these cyclization reactions are carried out in the presence of a base, the 6-ring bicyclic derivatives undergo rearrangement to their corresponding 5-ring pyrrolo-pyrimidin-2-one analogues **8** (*Scheme 2*). In the reaction of the triazolyl derivative **5** with 1-[(benzyloxy)carbonyl]-1-methylhydrazine, spontaneous cyclization gives the 5-ring derivative **13** related to **8** rather than the open-chain product **12** (*Scheme 4*). Reaction of an acetylated analogue of triazolyl derivative **5** with 1,1-dimethylhydrazine gives rise to some of the open-chain product **9**, but it too cyclizes to a product that we have assigned the structure of the 6,6-ring quaternary ammonium salt **11** (*Scheme 3*).

Introduction. – Nucleosides which are capable of base-pairing with more than one of the natural DNA/RNA bases are mutagenic. Such analogues are of use not only to explore aspects of chemical mutagenesis [1][2], but also as tools in molecular biology. We have extensively examined the mutagenic nucleoside **1**, which behaves as both thymidine and deoxycytidine. Its 5'-triphosphate has been used for random mutagenesis [3][4], whilst in oligonucleotides, it has been used in primers for PCR [5] and to study H-bonding patterns in DNA duplexes [6][7]. The analogue, however, does not behave indiscriminately as either T or C, but has a bias towards T. For this reason, we have for some time been examining alternative analogues that may shift this balance. The 5,6-ring (ribo) analogue **2** was prepared [8] in the expectation that the smaller ring size might have an effect on the tautomeric ratio. This, whilst appearing to behave more as a cytidine analogue in its ¹H-NMR spectrum, proved to be too unstable to investigate further.

N^4 -Hydroxycytosine derivatives have tautomeric constants (K_T) of the order of 10 with the imino (thymine-like) form predominating [9]. N^4 -Aminocytosine derivatives exist predominately in the amino form, with K_T of around 30 in H₂O. Whilst these compounds are highly mutagenic *in vivo*, N^4 -(alkylamino)cytosine derivatives are significantly less mutagenic [10]. This suggests that bicyclic analogues should show ambivalent base-pairing, but be less potent chemical mutagens. We, therefore, chose to

¹⁾ Present address: Consiglio Nazionale delle Ricerche, I.Co.C.E.A. Area della Ricerca, Via P. Gobetti, 101, I-40129, Bologna.




investigate N^4 -amino bicyclic analogues, such as **3**. The parent bicyclic compound **3** proved unstable; presumably it is susceptible to aerial oxidation. Therefore, we have attempted to prepare alkylated derivatives in the expectation that they would be stable, and that such compounds could then be used to investigate their ambivalent H-bonding behaviour in oligonucleotides.

Results and Discussion. – The 5-(2-chloroethyl)-2'-deoxyuridine derivative **4** [11] was converted to its C^4 -triazolyl derivative **5**, which was then subjected to a series of reactions with various hydrazines. Thus, reaction with anhydrous hydrazine led to the rapid displacement of the C^4 -triazolyl group, followed by a slower cyclization with the 5-(2-chloroethyl) group to give the bicyclic product **3** (*Scheme 1*). The product is rather unstable, readily degrading to a number of products, even if stored at 4°. Treatment of the C^4 -triazolyl derivative **5** with methylhydrazine under similar conditions led to an essentially single product, though in a slower reaction. Although in equivalent displacement reactions the N-atom carrying the Me group is the more nucleophilic, we hoped to obtain some of the desired **6** [10]. The structure of the 3',5'-di-*O*-acetyl rather than 3',5'-di-*O*-toluoyl derivative was elucidated by NOE experiments (no NOE on irradiation of MeN (3.14 ppm), irradiation of CH_2N (t , 2.97 ppm) $\rightarrow$ enhancement of the exchangeable signal and NOE at $\text{CH}_2(4)$ (2.51 ppm)). From this data, we deduced that the structure was not that of **6**, but of the regioisomer **7**.


It was observed that if the above cyclization reactions were carried out in the presence of a base, a second minor product was also formed (this product was also slowly formed on standing, particularly in solution). These minor products were rather difficult to separate from the first-formed 6,6-bicyclic products **3** and **7**. Therefore, **3** and **7** were treated with Et_3N or pyridine whereupon each was converted into this second product **8a** and **8b**, respectively, the methylated derivative **7** rearranging much slower than **3** (*Scheme 2*). Thus, the transformation of **3** in pyridine at 50° was complete after 16 h, whereas, under the same conditions, **7** had only reacted to *ca.* 50%. The rearrangement also occurred in 2,6-lutidine. The structures of **8a,b** were established as the 5-membered ring isomers from their ^1H -NMR spectra. The isomer **8a** was further characterized by conversion to its crystalline hydrazone with benzaldehyde, thus confirming the presence of the free NH_2 group.

The product **8a**, derived from **3**, showed a *s* (2 H) at 4.82 ppm for an unsubstituted NH_2 group. For the Me-substituted product **8b**, MeN group was a *d* (3.34 ppm), whilst the NH proton was a *q* (5.30 ppm). The MeN *d* collapsed to a *s* in the presence of D_2O .

Scheme 1




Scheme 2



To investigate the formation of the 5-membered ring bicyclic analogues further, the 3',5'-di-*O*-acetyl-substituted analogue of **5** was reacted with 1,1-dimethylhydrazine (Scheme 3). This was expected to give **9**, which we then planned to use to examine whether cyclization would occur leading to the 5-ring **10**. Displacement of the triazolyl group of the di-*O*-acetyl analogue of **5** by 1,1-dimethylhydrazine in tetrachloroethane at 100° overnight gave the expected product **9** in low yield, besides a major product which was polar, water-soluble, and very difficult to isolate in pure form. In an earlier

Scheme 3




preliminary report [12], we suggested that this product was the quaternary ammonium salt **11**. This assignment was based on the fact that the product is water-soluble and polar: it has a mass spectrum with M^+ at m/z 381 and a ^1H -NMR spectrum corresponding to the proposed structure **11**. Isolation of the pure product has been attempted by a variety of methods including ion-exchange and reversed-phase HPLC, but has so far eluded us and is the subject of further work. It is anticipated that we may be able to demethylate the purified product to give the desired bicyclic di-*O*-acetyl analogue of **6**. Interestingly, we have no evidence, despite attempting the reaction many times under a variety of conditions, that ring contraction to the 5-ring analogue **10** occurred.

The ^1H -NMR spectrum of the salt **11** shows a s (6 H) at 3.15 ppm for Me_2N^+ , whereas for the dimethylhydrazine product **9**, there is a s (6 H) at 2.50 ppm. This is consistent with the change in chemical shift for Me_2N to Me_2N^+ . Thus, the data are entirely consistent with the structure of **11** being the 6-ring quaternary ammonium derivative.

As the methylamino residue of methylhydrazine is evidently the more nucleophilic group [13], it was decided to use a protected methylhydrazine derivative as an alternative route to produce the analogue **6**. Once deprotected, the methylamino residue could undergo cyclization with the 5-(chloroethyl) side chain. Thus, reaction of the triazolyl derivative **5** with 1-[(benzyloxy)carbonyl]-1-methylhydrazine [14] gave a product that we initially believed to be the expected compound **12** in a slow reaction (Scheme 4). On this assumption, we reductively removed the (benzyloxy)carbonyl (Z) group using either Pt or Pd in MeOH. However, the product that we obtained was not the desired product but again the 5-membered-ring derivative **8b**, as established by its ^1H -NMR spectrum, and comparison with the product **8b** obtained by ring contraction from **7** (see above). We therefore assumed that the product had preferentially cyclized or rearranged with N^4 as the (benzyloxy)carbonyl protecting group was being removed. Thus, the reduction was carried out in acid (AcOH or 0.1M HCl), as we hoped that protonation of the amino group would prevent ring closure after removal of the Z protecting group. This would then enable cyclization to occur to give the desired regiospecific product following neutralization. However, the product **14** obtained was again a 5-ring derivative related to **8**; moreover, under these conditions, the methylamino group had been reductively cleaved (Scheme 4).


Subsequently, we found that the intermediate (Z-protected) reaction product, initially assigned the structure **12**, was in fact the cyclized reaction product **13** (see

Scheme 4



Scheme 4). This was confirmed by the MS of **13**, which showed an ion at m/z 675 ($[M + \text{Na}]^+$), corresponding to the loss of HCl from **12**. Thus cyclization must have occurred after displacement of the triazole moiety and prior to reduction. The open-chain intermediate **12** was never observed in this reaction despite using a variety of alternative reaction conditions. The formation of the 5-membered ring bicyclic product is surprising. In this connection, when the triazole **5** was treated with ammonia, the cytidine derivative **15** was formed which did not undergo cyclization (*Scheme 5*). Neither did the *N*-hydroxycytidine derivative **16** [15] cyclize to give the corresponding bicyclic product. The presence of the Z group at the methylhydrazine renders it particularly unreactive, both in terms of the initial nucleophilic displacement of the C⁴-triazolyl group and towards further cyclization.


Scheme 5



It is of interest to speculate on the nature of the formation of the bicyclic compound **13**. We have previously experienced the fact that the chloroethyl side chain is particularly unreactive towards nucleophilic displacement reactions, except for intramolecular cyclization. Therefore, the formation of **13** probably does not arise by first displacing chloride, followed by cyclization. However, the cyclization of the chloroethyl group to form a bicyclic compound is, nevertheless, a slow reaction, compared to the nucleophilic displacement of the C⁴-triazolyl group. Although the Z-protected hydrazine is particularly unreactive, it appears that, once the initial reaction to displace the triazole moiety has occurred, cyclization with the chloroethyl group is spontaneous.

Lastly, we turn to the question of the mechanism whereby the 6,6-ring hydrazine derivatives of type **7** rearrange to 5,6-ring isomers, carrying an N^4 -amino function in the cytosine moiety (see *Scheme 2*). The evidence is strong that the first-formed products are the 6,6-ring bicyclic compounds of type **7** and result from a displacement first of the triazolyl residue of **5** followed by ring closure. Rearrangement is base-catalysed and occurs in the cases where the N^4 -amino N-atom carries a proton. Two mechanisms suggest themselves (*Scheme 6*). In the first, an intramolecular displacement at C(4) by the N^4 -amino group occurs, *via* a strained transition entity **17**. Alternatively, if the base is acting as a nucleophile, an intermediate **18** may be postulated which would lead in a second displacement reaction to the thermodynamically and kinetically favoured 5-membered ring product. The fact that the rearrangement occurs in 2,6-lutidine strongly suggests that the first mechanism is the more likely route.

Scheme 6



Experimental Part

General. Unless otherwise stated, reactions were worked up as follows: After removal of the solvent, the product was dissolved in CHCl_3 and washed with aq. sodium hydrogen carbonate soln. The combined org. fractions were dried (Na_2SO_4) and evaporated. TLC: pre-coated F_{254} silica gel plates. Column chromatography (CC): Merck silica gel 60 or reversed-phase column LiChroprep RP-18 (Merck). M.p.: Gallenkamp melting point apparatus; uncorrected. UV Spectra: Perkin-Elmer-Lambda-2 spectrophotometer; in 10% MeOH/ H_2O unless otherwise stated; λ_{max} (ϵ) in nm. $^1\text{H-NMR}$ Spectra: Bruker DRX 300; in $(\text{D}_6)\text{DMSO}$, unless otherwise stated; δ in ppm, J values in Hz. NOE Experiments: Bruker-AMX-500 spectrometer. Mass spectra: Kratos MS890; in m/z (rel. %).

5-(2-Chloroethyl) 1-[2-deoxy-(3,5-di- O -(p -toluoyl)- β -D-ribofuranosyl]-4-(1H-1,2,4-triazol-1-yl)pyrimidin-1(1H)-one (5**).** To a suspension of 1H-1,2,4-triazole (4.72 g, 68.3 mmol) in dry MeCN (100 ml) at 0° , phosphoric trichloride (1.27 ml, 13.7 mmol) was added dropwise, and the mixture was stirred at 0° for 15 min. After this time, dry Et_3N (11.5 ml, 82 mmol) was added and the mixture stirred at 0° for a further 20 min, then at r.t. for 10 min. A soln. of 5-(2-chloroethyl)-1-[2-deoxy-3,5-di- O -(p -toluoyl)- β -D-ribofuranosyl]pyrimidine-2,4-(1H,3H)-dione [11] (2.4 g, 4.5 mmol) in dry MeCN (10 ml) and DMF (10 ml) was then added dropwise with vigorous stirring. The mixture was kept under Ar at r.t. overnight and then evaporated. The residue was dissolved in CHCl_3 , the soln. washed with aq. NaHCO_3 soln., dried, and evaporated, and the orange syrup purified by CC (silica gel, AcOEt/hexane 1:1): 2.27 g (86%) of **5**. White solid. UV: 323 (5200), 242 (33200), min. 216 (14200). M.p. 155–157°. $^1\text{H-NMR}$: 2.28 (s, MeC_6H_4); 2.39 (s, MeC_6H_4); 2.59–2.68 (m, 1 H–C(2'')); 2.87–3.17 (m, 1 H–C(2'), $\text{CH}_2\text{CH}_2\text{Cl}$); 3.57 (t, $J=7.1$, $\text{CH}_2\text{CH}_2\text{Cl}_2$); 4.56–4.74 (m, H–C(4'), 2 H–C(5'')); 5.62–5.65 (m, H–C(3'')); 6.28 (t, $J=6.5$, H–C(1'')); 7.22, 7.36, 7.76, 7.93 (4 d, 8 arom. H (Tol)); 8.37 (s, H–C(6)); 8.40 (s, CH(triazole)); 9.36 (s, CH(triazole)). FAB-MS: 578.8 ($[M+H]^+$). HR-MS: 578.18268 ($[M+H]^+$, $\text{C}_{29}\text{H}_{29}\text{N}_5\text{O}_6^{35}\text{Cl}^+$; calc. 578.18066; deviation –3.50 ppm).

6-[2-Deoxy-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl]-2,3,4,6-tetrahydropyrimido[4,5-c][1,2]pyridazin-7(1H)-one (3). To a soln. of **5** (0.25 g, 0.43 mmol) in dry MeCN (10 ml), anh. hydrazine (20 μl, 0.64 mmol) was added, and the soln. was stirred at r.t. for 2 h. The soln. was concentrated and chromatographed (5% MeOH/CHCl₃): 0.19 g (87%) of **3**. White solid. UV: 278 (10900), 244 (33300), min. 269 and 218; pH 1: 274 (10600), 240 (31850), min. 269 and 233; pH 12: 274 (10500), 240 (31750), min. 268 and 233. ¹H-NMR: 2.37 (s, MeC₆H₄); 2.38 (s, MeC₆H₄); 2.43–2.63 (m, CH₂, 2 H–C(2')); 3.32 (br. s, NH); 3.49–3.69 (m, CH₂N); 4.44–4.48 (m, H–C(4')); 4.50–4.63 (m, 2 H–C(5')); 5.56 (br. s, H–C(3')); 6.28–6.37 (m, H–C(1')); 7.10 (s, H–C(5)); 7.31–7.36 (m, 4 arom. H (Tol)); 7.86–8.31 (m, 4 arom. H (Tol)); 9.64 (br. s, NH). FAB-MS: 505.9 ([M+H]⁺). HR-MS: 505.20813 ([M+H]⁺, C₂₇H₂₉N₄O₆⁺; calc. 505.20871; deviation 1.10 ppm).

6-[2-Deoxy-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl]-2,3,4,6-tetrahydro-1-methylpyrimido[4,5-c][1,2]pyridazin-7(1H)-one (7). To a soln. of **5** (0.25 g, 0.43 mmol) in MeCN (10 ml), methylhydrazine (35 μl, 0.66 mmol) was added and the soln. stirred at r.t. for 8 h. The soln. was evaporated and the residue chromatographed (5% MeOH/CHCl₃): 0.19 g (85%) of **7**. Off-white foam. UV 285 (12100), 243 (38700), min. 218 and 273; pH 1: 303 (14950), 244 (41700), min. 216 and 269; pH 12: 285 (13200), 239 (37600), min. 229 and 266. ¹H-NMR: 2.22–2.32 (m, 2 H–C(4)); 2.37 (s, MeC₆H₄); 2.38 (s, MeC₆H₄); 2.37–2.54 (m, 2 H–C(2')); 2.88 (m, CH₂N); 3.12 (s, MeN); 4.46–4.48 (m, H–C(4')); 4.51–4.65 (m, 2 H–C(5')); 5.52 (t, J = 6.9, NH); 5.56–5.59 (m, H–C(3')); 6.33 (t, J = 6.3, H–C(1')); 7.31–7.37 (m, 4 arom. H (Tol)); 7.34 (s, H–C(5)); 7.86–7.92 (m, 4 arom. H (Tol)). FAB-MS: 519.8 ([M+H]⁺). HR-MS: 519.22802 ([M+H]⁺, C₂₈H₃₁N₄O₆⁺; calc. 519.22437; deviation –7.0 ppm).

In the same manner the 3',5'-di-O-acetyl instead of 3',5'-di-O-toluoyl derivative was prepared. White foam. UV: 292, 229, min. 250; pH 1: 305, min. 252. ¹H-NMR: 2.06 (s, Ac); 2.07 (s, Ac); 2.24–2.30 (m, 2 H–C(2')); 2.51 (m, 2 H–C(4)); 2.97 (t, J = 5.7, CH₂N); 3.14 (s, MeN); 4.12–4.17 (m, H–C(4')); 4.22–4.25 (m, 2 H–C(5')); 5.15–5.19 (m, H–C(3')); 5.59 (t, J = 5.7, NH); 6.24 (t, J = 6.7, H–C(1')); 7.38 (s, H–C(5)). EI-MS: 366 ([M+H]⁺). HR-MS: 366.1572 ([M+H]⁺, C₁₆H₂₂N₄O₆⁺; deviation 3.2 ppm).

7-Amino-3-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl]-3,5,6,7-tetrahydro-2H-pyrrolo[2,3-d]pyrimidin-2-one (8a). A soln. of **3** (200 mg, 0.6 mmol) in MeCN (10 ml) and Et₃N (1 ml) was heated under reflux overnight. Alternatively, a soln. of **3** was stirred in pyridine at r.t. overnight. After evaporation, the product was chromatographed (5% MeOH/CHCl₃): 146 mg (73%) of **8a**. White foam. UV: 283 (10400), 245 (32000), min. 270 and 215; pH 1: 286 (11100), 244 (29800), min. 270 and 215. ¹H-NMR: 2.37 (s, MeC₆H₄); 2.38 (s, MeC₆H₄); 2.44–2.58 (m, 2 H–C(2'), CH₂); 3.58 (t, J = 7.5, CH₂N); 4.22–4.23 (m, H–C(4')); 4.50–4.63 (m, 2 H–C(5')); 4.82 (s, NH₂); 5.54–5.56 (m, H–C(3')); 6.36 (t, J = 7.8, H–C(1')); 7.27 (s, H–C(4)); 7.32–7.36 (m, 4 arom. H (Tol)); 7.86–7.91 (m, 4 arom. H (Tol)). FAB-MS: 505.9 ([M+H]⁺), 527.9 ([M+Na]⁺). HR-MS: 527.18983 ([M+Na]⁺, C₂₇H₂₈N₄O₆Na⁺; calc. 527.19067; deviation 1.60 ppm).

Benzaldehyde Hydrazone of 8a: After treatment of **8a** with benzaldehyde in CH₂Cl₂, the soln. was evaporated and the residue chromatographed (2% MeOH/CHCl₃): pale yellow solid which recrystallized from EtOH. M.p. 200–202°. UV: 327 (23900), 240 (21200), min. 272 and 222; pH 1: 334 (17800), 247 (19600), min. 296 and 226; pH 12: 328 (24200), 240 (21000), min. 272. ¹H-NMR: 2.35 (s, MeC₆H₄); 2.39 (s, MeC₆H₄); 2.43–2.63 (m, 2 H–C(2')); 2.71–2.88 (m, CH₂); 3.94–4.00 (m, CH₂(6)), 4.51–4.58 (m, H–C(4')); 4.59–4.67 (m, 2 H–C(5')); 5.57–5.60 (m, H–C(3')); 6.36 (t, J = 7.5, H–C(1')); 7.31–7.37 (m, 4 arom. H (Tol)); 7.40–7.47 (3 H, m, 3 arom. H (Ph)); 7.63 (s, H–C(4)); 7.74 (1 H, s, 1 arom. H (Ph)); 7.77 (s, N=CH); 7.90 (s, 1 arom. H (Ph)); 7.86–7.95 (m, 4 arom. H (Tol)). FAB-MS: 593.24 ([M+H]⁺). HR-MS: 593.23926 ([M+H]⁺, C₃₄H₃₃N₄O₆⁺; calc. 593.23999; deviation 1.20 ppm).

3-[2-Deoxy-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl]-3,5,6,7-tetrahydro-7-(methylamino)-2H-pyrrolo[2,3-d]pyrimidin-2-one (8b) (Method A). A soln. of **7** (150 mg, 0.29 mmol) in MeCN (10 ml) and Et₃N (0.5 ml) was heated under reflux overnight. After evaporation, the product was chromatographed (5% MeOH/CHCl₃) to give a white solid which was recrystallized from EtOH: 124 mg (83%) of **8b**. UV: 283 (10800), 244 (31900), min. 269 and 217; pH 1: 293 (12800), 244 (32900), min. 268 and 216; pH 12: 283 (11900), 240 (31700), min. 265 and 229. M.p. 175–176°. ¹H-NMR: 2.37 (s, MeC₆H₄); 2.38 (s, MeC₆H₄); 2.49–2.65 (m, 2 H–C(2'), CH₂(5)); 3.34 (d, MeN, s after D₂O wash); 3.59 (t, J = 7.5, CH₂(6)); 4.43–4.63 (m, H–C(4'), 2 H–C(5')); 5.30 (q, J = 5.7, exchangeable NH); 5.50–5.60 (m, H–C(3')); 6.34 (t, J = 7.6, H–C(1')); 7.31–7.36 (m, H–C(4), 4 arom. H (Tol)); 7.85–7.91 (m, 4 arom. H (Tol)). FAB-MS: 519.3 ([M+H]⁺). HR-MS: 519.22380 ([M+H]⁺, C₂₈H₃₁N₄O₆⁺; calc. 519.22437; deviation 1.10 ppm). Anal. calc. for C₂₈H₃₀N₄O₆: C 64.9, H 5.8, N 10.8; found: C 64.93, H 5.87, N 10.80.

6-(3,5-Di-O-acetyl-2-deoxy-β-D-ribofuranosyl)-1,2,3,4,6,7-hexahydro-2,2-dimethyl-7-oxopyrimido[4,5-c][1,2]pyridazinium (11). To a soln. of the 3',5'-di-O-acetyl-substituted analog of **5** [16] (1 g, 1.7 mmol) in tetrachloroethane (25 ml), 1,1-dimethylhydrazine (0.4 ml, 5.3 mmol) was added and the soln. heated at 100° overnight (TLC: two main products, one with R_f 0). The product was extracted (H₂O/CHCl₃), and each of the

two layers was evaporated. The org. layer was chromatographed (5% MeOH/CHCl₃) to give an off-white foam, which was characterized as 5-(2-chloroethyl)-1-(3,5-di-O-acetyl-2-deoxy-β-D-ribofuranosyl)-N⁴-(dimethylamino)cytosine (**9**; 0.32 g, 33%). Off-white foam. ¹H-NMR: 2.06 (s, Ac); 2.07 (s, Ac), 2.22–2.36 (m, 2 H–C(2'')); 2.50 (s, Me₂N); 2.95–3.05 (m, CH₂); 3.14 (s, CH₂Cl); 4.12–4.19 (m, H–C(4'')); 4.23–4.25 (m, 2 H–C(5'')); 5.14–5.19 (m, H–C(3'')); 5.59 (br. s, NH); 6.24 (t, *J* = 6.7, H–C(1'')); 7.38 (s, H–C(6)). EI-MS: 417 (*M*⁺).

The aq. layer was evaporated and purified by CC (reversed-phase *C-18* silica gel, H₂O → 25% MeOH/H₂O): 0.28 g (31%) of **11**. Brown foam. ¹H-NMR: 2.06 (s, Ac); 2.07 (s, Ac); 2.12–2.32 (m, 2 H–C(2'')); 2.79 (t, *J* = 5.3, CH₂); 3.15 (s, Me₂N⁺); 3.44 (t, *J* = 5.6, CH₂N); 4.06–4.10 (m, H–C(4'')); 4.20–4.27 (m, 2 H–C(5'')); 5.14–5.16 (m, H–C(3'')); 6.24–6.30 (m, H–C(1'')); 7.23 (s, H–C(6)); 8.24 (s, NH). EI-MS: 381 (*M*⁺).

7-[(Benzoyloxy)carbonyl]methylamino]-3-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl]-3,5,6,7-tetrahydro-2H-pyrrolo[2,3-d]pyrimidin-2-one (**13**). To a soln. of **5** (0.5 g, 0.865 mmol) in tetrachloroethane (10 ml), 1-[(benzyloxy)carbonyl]-1-methylhydrazine [14] (0.38 g, 2.14 mmol) was added and the soln. heated at 85° overnight. After dilution with CHCl₃ and workup as described, the product was chromatographed (AcOEt/hexane/MeOH 1:1:0 → 7:3:0.1): 0.52 g (97%) of **13**. Off-white solid. UV: 283 (10400), 241 (34800), min. 267 and 219; pH 1: 300 (9900), 245 (24200), min. 269. ¹H-NMR: 2.37 (s, MeC₆H₄); 2.39 (s, MeC₆H₄); 2.53–2.72 (m, 2 H–C(2''), CH₂(5)); 3.08 (s, MeN); 3.60–3.82 (m, CH₂(6)); 4.48–4.63 (m, H–C(4'')); 2 H–C(5'')); 5.09–5.14 (m, CH₂); 5.56–5.58 (m, H–C(3'')); 6.33 (t, *J* = 7.3, H–C(1'')); 7.22–7.39 (m, 8 arom. H); 7.56 (s, H–C(4)); 7.84–7.92 (m, 5 arom. H). FAB-MS: 675.2448 ([*M* + Na]⁺). HR-MS: 675.2448 ([*M* + Na]⁺, C₃₆H₃₆N₄O₈Na⁺; calc. 652.2431; deviation 2.50 ppm).

Pyrrolopyrimidinone **8b** (Method B). To a soln. of **13** (0.4 g, 0.6 mmol) in dry MeOH (20 ml), 10% Pd/C (or PtO₂) catalyst (50 mg) was added and the soln. stirred under H₂ for 2 h. The suspension was filtered through Celite and the cake washed with MeOH. The solvent was evaporated and the residue chromatographed (5% MeOH/CHCl₃): 0.25 g (79%) of **8b**. White solid. For data, see above (Method A).

3-[2-Deoxy-3,5-di-O-(p-toluoyl)-β-D-2-ribofuranosyl]-3,5,6,7-tetrahydro-2H-pyrrolo[2,3-d]pyrimidin-2-one (**14**). To a soln. of **13** (0.4 g, 0.6 mmol) in AcOH (20 ml), Adam's catalyst (50 mg) was added and the soln. stirred under H₂ for 4 h. Workup and FC as described for **8b** (Method B) gave **16** (0.13 g, 43%). White solid. UV: 277 (8400), 244 (32800), min. 265 and 216; pH 1: 285 (9500), 244 (31600), min. 269 and 220. ¹H-NMR: 2.37 (s, MeC₆H₄); 2.38 (s, MeC₆H₄); 2.42–2.49 (m, 2 H–C(2'')); 2.61–2.69 (m, CH₂); 3.49 (t, *J* = 7.8, CH₂(6)); 4.43–4.44 (m, H–C(4'')); 4.50–4.63 (m, 2 H–C(5'')); 5.55–5.57 (m, H–C(3'')); 6.34 (t, *J* = 7.9, H–C(1'')); 7.32–7.37 (m, H–C(6), 4 arom. H (Tol)); 7.86–7.92 (m, 4 arom. H (Tol)); 7.99 (s, NH). FAB-MS: 490.7 ([*M* + H]⁺). HR-MS: 490.19792 ([*M* + H]⁺, C₂₇H₂₈N₃O₆⁺; calc. 490.19781; deviation –0.20 ppm).

5-(2-Chloroethyl)-1-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl]cytosine (**15**). A soln. of **5** (0.25 g, 0.43 mmol) in ammonia-saturated dioxane (10 ml) was stirred at r.t. overnight. The soln. was evaporated and the product chromatographed (5% MeOH/CHCl₃) to give a white solid. Attempts to recrystallize resulted in gel formation: 0.22 g (97%) of **15**. UV: 248 (23000), 272 (sh), min. 232; pH 1: 285 (11000), 245 (29300), min. 220 and 268. ¹H-NMR: 2.37 (s, MeC₆H₄); 2.39 (s, MeC₆H₄); 2.44–2.57 (m, 2 H–C(2''), CH₂); 3.53 (t, *J* = 7, CH₂Cl); 4.47–4.64 (m, H–C(4''), 2 H–C(5'')); 5.57–5.59 (m, H–C(3'')); 6.31 (t, *J* = 7.6, H–C(1'')); 7.09 (br. s, NH₂); 7.30–7.36 (m, 4 arom. H (Tol)); 7.47 (s, H–C(6)); 7.85–7.92 (m, 4 arom. H (Tol)). FAB-MS: 526.9 ([*M* + H]⁺), 548.9 ([*M* + Na]⁺). HR-MS: 548.15620 ([*M* + Na]⁺, C₂₇H₂₈N₃O₆³⁵ClNa⁺; calc. 548.15643; deviation 0.40 ppm).

We thank Dr. David Neuhaus for the NOE experiments, Dr. Mao Jun Guo for helpful discussions, and Nycomed Amersham plc for financial assistance.

REFERENCES

- [1] M. J. Stone, A. N. R. Nedderman, D. H. Williams, P. Kong Thoo Lin, D. M. Brown, *J. Mol. Biol.* **1991**, 222, 711.
- [2] K. Negishi, D. M. Williams, Y. Inoue, K. Moriyama, D. M. Brown, H. Hayatsu, *Nucleic Acids Res.* **1997**, 25, 1548.
- [3] M. Zaccolo, D. M. Williams, D. M. Brown, E. Gherardi, *J. Mol. Biol.* **1996**, 255, 589.
- [4] M. Zaccolo, E. Gherardi, *J. Mol. Biol.* **1999**, 285, 775.
- [5] F. Hill, D. Loakes, D. M. Brown, *Proc. Natl. Acad. Sci. U.S.A.* **1998**, 95, 4258.
- [6] M. H. Moore, L. Van Meervelt, S. A. Salisbury, P. Kong Thoo Lin, D. M. Brown, *J. Mol. Biol.* **1995**, 251, 665.
- [7] G. S. Schuerman, L. Van Meervelt, D. Loakes, D. M. Brown, P. K. T. Lin, M. H. Moore, S. A. Salisbury, *J. Mol. Biol.* **1998**, 282, 1005.

- [8] D. Loakes, D. M. Brown, *Nucleosides Nucleotides*, **1994**, 13, 679.
- [9] D. M. Brown, M. J. E. Hewlins, P. Schell, *J. Chem. Soc. (C)* **1968**, 1925.
- [10] A. Nomura, K. Negishi, H. Hayatsu, *Nucleic Acids Res.* **1985**, 13, 8893.
- [11] H. Griengl, M. Bodenteich, W. Hayden, E. Wanek, W. Streicher, P. Stutz, H. Bachmayer, I. Ghazzouli, B. Rosenwirth, *J. Med. Chem.* **1985**, 28, 1679.
- [12] D. Loakes, D. M. Brown, *Nucleosides Nucleotides* **1995**, 14, 291.
- [13] D. E. Butler, S. M. Alexander, J. W. McLean, L. B. Strand, *J. Med. Chem.* **1971**, 1052.
- [14] S. A. Dutta, J. S. Morley, *J. Chem. Soc., Perkin Trans. 1*, **1975**, 1712.
- [15] P. Kong Thoo Lin, D. M. Brown, *Heterocycles* **1989**, 29, 1735.
- [16] P. Kong Thoo Lin, D. M. Brown, *Nucleic Acids Res.* **1989**, 17, 10373.

Received August 20, 1999